TY - JOUR
T1 - Antimicrobial resistance and antibiotic consumption in intensive care units, Switzerland, 2009 to 2018
AU - on behalf of the Swiss Centre for Antibiotic Resistance (ANRESIS)4
AU - Barnsteiner, Stefanie
AU - Baty, Florent
AU - Albrich, Werner C.
AU - Flury, Baharak Babouee
AU - Gasser, Michael
AU - Plüss-Suard, Catherine
AU - Schlegel, Matthias
AU - Kronenberg, Andreas
AU - Kohler, Philipp
AU - Cherkaoui, A.
AU - Dubuis, O.
AU - Egli, A.
AU - Gaia, V.
AU - Gottwalt, S.
AU - Jayol, A.
AU - Kronenberg, A.
AU - Leib, S. L.
AU - Marschall, J.
AU - Matter, H.
AU - Nordmann, P.
AU - Perreten, V.
AU - Piffaretti, J. C.
AU - Prod'hom, G.
AU - Stärk, K.
AU - Schrenzel, J.
AU - Widmer, A. F.
AU - Zanetti, G.
AU - Zbinden, R.
N1 - Funding Information:
This laboratory-based surveillance study was conducted using antimicrobial resistance and antibiotic consumption data from ANRESIS (www.anresis.ch). ANRESIS, led by the Institute for Infectious Diseases at the University of Bern, is the national centre for surveillance of antibiotic resistance and antibiotic consumption and is supported by the Swiss Federal Office of Public Health. Antimicrobial susceptibility testing is performed at local laboratories according to guidelines from the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [12,13]. All laboratories are accredited by Swiss authorities and participate in at least one external quality programme of either the National External Quality Assessment Service (https://ukneqas.org.uk) or the Swiss quality control programme of the Institute for Medical Microbiology, University of Zurich (www.imm.uzh.ch/de/services/ qc.html).
Funding Information:
Funding: This work was supported by the research fund of the Cantonal Hospital St.Gallen. PK is funded by the Swiss National Science Foundation (grant No PZ00P3_179919).
Publisher Copyright:
© 2021 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2021/11/18
Y1 - 2021/11/18
N2 - Background: Intensive care units (ICU) constitute a high-risk setting for antimicrobial resistance (AMR). Aim: We aimed to describe secular AMR trends including meticillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci (GRE), extended-spectrum cephalosporin-resistant Escherichia coli (ESCR-EC) and Klebsiella pneumoniae (ESCR-KP), carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CRPA) from Swiss ICU. We assessed time trends of antibiotic consumption and identified factors associated with CRE and CRPA. Methods: We analysed patient isolate and antibiotic consumption data of Swiss ICU sent to the Swiss Centre for Antibiotic Resistance (2009-2018). Time trends were assessed using linear logistic regression; a mixed-effects logistic regression was used to identify factors associated with CRE and CRPA. Results: Among 52 ICU, MRSA decreased from 14% to 6% (p = 0.005; n = 6,465); GRE increased from 1% to 3% (p = 0.011; n = 4,776). ESCR-EC and ESCR-KP increased from 7% to 15% (p < 0.001, n = 10,648) and 5% to 11% (p = 0.002; n = 4,052), respectively. CRE, mostly Enterobacter spp., increased from 1% to 5% (p = 0.008; n = 17,987); CRPA remained stable at 27% (p = 0.759; n = 4,185). Antibiotic consumption in 58 ICU increased from 2009 to 2013 (82.5 to 97.4 defined daily doses (DDD)/100 bed-days) and declined until 2018 (78.3 DDD/100 bed-days). Total institutional antibiotic consumption was associated with detection of CRE in multivariable analysis (odds ratio per DDD: 1.01; 95% confidence interval: 1.0-1.02; p = 0.004). Discussion: In Swiss ICU, antibiotic-resistant Enterobacterales have been steadily increasing over the last decade. The emergence of CRE, associated with institutional antibiotic consumption, is of particular concern and calls for reinforced surveillance and antibiotic stewardship in this setting.
AB - Background: Intensive care units (ICU) constitute a high-risk setting for antimicrobial resistance (AMR). Aim: We aimed to describe secular AMR trends including meticillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci (GRE), extended-spectrum cephalosporin-resistant Escherichia coli (ESCR-EC) and Klebsiella pneumoniae (ESCR-KP), carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CRPA) from Swiss ICU. We assessed time trends of antibiotic consumption and identified factors associated with CRE and CRPA. Methods: We analysed patient isolate and antibiotic consumption data of Swiss ICU sent to the Swiss Centre for Antibiotic Resistance (2009-2018). Time trends were assessed using linear logistic regression; a mixed-effects logistic regression was used to identify factors associated with CRE and CRPA. Results: Among 52 ICU, MRSA decreased from 14% to 6% (p = 0.005; n = 6,465); GRE increased from 1% to 3% (p = 0.011; n = 4,776). ESCR-EC and ESCR-KP increased from 7% to 15% (p < 0.001, n = 10,648) and 5% to 11% (p = 0.002; n = 4,052), respectively. CRE, mostly Enterobacter spp., increased from 1% to 5% (p = 0.008; n = 17,987); CRPA remained stable at 27% (p = 0.759; n = 4,185). Antibiotic consumption in 58 ICU increased from 2009 to 2013 (82.5 to 97.4 defined daily doses (DDD)/100 bed-days) and declined until 2018 (78.3 DDD/100 bed-days). Total institutional antibiotic consumption was associated with detection of CRE in multivariable analysis (odds ratio per DDD: 1.01; 95% confidence interval: 1.0-1.02; p = 0.004). Discussion: In Swiss ICU, antibiotic-resistant Enterobacterales have been steadily increasing over the last decade. The emergence of CRE, associated with institutional antibiotic consumption, is of particular concern and calls for reinforced surveillance and antibiotic stewardship in this setting.
UR - http://www.scopus.com/inward/record.url?scp=85121236673&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2021.26.46.2001537
DO - 10.2807/1560-7917.ES.2021.26.46.2001537
M3 - Article
C2 - 34794535
AN - SCOPUS:85121236673
SN - 1025-496X
VL - 26
JO - Eurosurveillance
JF - Eurosurveillance
IS - 46
ER -